XGX Pharma ApS: Financial statements 2020
CVR: 32289290
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 15,225,623 and a net result of DKK 6,004,347 compared with DKK 8,356,668 the year before. That is an increase of 29.9% compared with the year before. Equity in the 2020 report amounted to DKK 12,920,362. The solvency ratio was 51.8%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 15,225,623
- Profit/Loss
- DKK 6,004,347
- Equity
- DKK 12,920,362
- Total Assets
- DKK 24,937,589
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 15.2 mio. | 6 mio. | 12.9 mio. | 3 |
| 2019 | - | 11.7 mio. | 8.4 mio. | 11.4 mio. | 3 |
| 2018 | - | 1.6 mio. | 27 t. | 59 t. | 1 |
| 2017 | - | 104 t. | -189 t. | 32 t. | - |
| 2016 | - | 307 t. | 272 t. | 92 t. | - |
Official annual report
How creditworthy is XGX Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
XGX Pharma ApS has published its annual report for 2019. Gross profit came to DKK 11,716,951, and the net result was DKK 8,356,668.
As of February 14, 2020, Kreston CM Statsautoriseret Revisions interessentskab has been appointed auditor of XGX Pharma ApS.
As of February 14, 2020, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of XGX Pharma ApS.
As of January 27, 2020, Rolf Eckersberg has joined the board of directors of XGX Pharma ApS.
As of January 27, 2020, Per Ludvigsen has left the board of directors of XGX Pharma ApS.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.